Keywords: drug, insurance system, health, diseases, co-payment, pharmacies, out-of-pocket expenditure


The increase in the cost of the medicinal component of the treatment, the spread of chronic diseases, and the maintenance of socio-economic inequality in access to health services require the provision of adequate access to medicines. These issues create prerequisites for the improvement of the state health policy and, first, the drug supply system, which is an integral part of the treatment process. The financing of healthcare in Armenia is mainly formed from budget allocations and out of pocket expenditures of the population. Reducing the financial burden on the state and ensuring the rational use of drugs contributes to improving the health of the population. The implementation of a drug insurance scheme, which partially or fully cover the cost of drugs in RA, is one of the solutions for resolving the issue of access to medicines. This article studies the problems of financing healthcare system in Armenia and highlights the need of introduction a drug insurance system in Armenia


Berkeley, B. (2017) Relationship between Health Provider Status and Social Interaction. Open Access Library Journal, 4, 1-7. DOI: 10.4236/oalib.1103708

Mateu C, Guerlain A. (2019) Global Legal Insights - Pricing & Reimbursement 2019, Second Edition, pp. 65-83. Retrieved from

Current health expenditure (% of GDP). World Health Organization Global Health Expenditure database ( The data was retrieved on January 30, 2022.

Finance Statistics of Armenia 2015-2020. Retrieved from

Global expenditure on health: public spending on the rise? Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Gottret, P., and G. Schieber. 2006. Health Financing Revisited: A Practitioner’s Guide. Washington, D.C.: World Bank, pp.340. Retrieved from

Hayrapetyan N. (2018), State regulation of the health sector and contemporary problems of management in the RA, pp.121. Retrieved from

Tracking universal health coverage, Global Monitoring Report on Universal Health Coverage 2021 (as of 12th December 2021), pp. 103. Retrieved from

Nguyen T, Rosemary Knight, Roughead E, Brooks G. and Mant A. (2013) Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries, Health Policy and Planning 2015;30:267–280 doi:10.1093/heapol/czt105, Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine, pp. 267-280. Retrieved from

Ozieranski P. & King L. (2017) Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector, Theor Soc (2017) 46:577–610, pp. 577-610. Retrieved from

Ngorsuraches S, Meng W., Kim B., Kulsomboon V. (2011) Drug Reimbursement Decision-Making in Thailand, China, and South Korea, Volume 15, Issue 1, Supplement, January–February 2012, p. 120-125, rights and content, Under an Elsevier user license. Retrieved from

S. Aghajanyan (2020). Will Armenia’s Healthcare System Hold the Impact of a Protracted Pandemic?, Amberd Bulletin 2020/2, pp. 32-37, Retrieved from

World Bank Data, Retrieved from

World Health Organization (2018) Medicines Reimbursement Policies in Europe, pp. 200,

Варианты политики в сфере возмещения стоимости лекарственных средств в Европе (2018) p. 31

Попович Л. (2019) Лекарственное страхование – выбор пути, с. 6-16. DOI:–5936–2019–04-6-16. Retrieved from

Глембоцкая Г., Богатырев С. (2009) Страхование лекарственного обеспечения как средство повышения качества медицинской помощи, ВЕСТНИК ВГУ, серия: химия. биология. фармация, 2009, № 1, ст. 107-112, Retrieved from

Retrieved from





How to Cite
Susanna Aghajanyan, Lusine Karapetyan, Arsen Petrosyan, Tatevik Vardanyan, Tigran Mikayelyan, Anna Ayvazyan, & Gagik Hakobyan. (2022). THE NECESSITY OF INTRODUCTION THE DRUG INSURANCE SYSTEM IN ARMENIA. World Science, (5(77).